These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12470422)

  • 21. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
    Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
    Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiosynthesis and Preclinical Evaluation of
    Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
    Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
    Petrik M; Laznickova A; Laznicek M; Zalutsky MR
    Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
    Breeman WA; de Jong M; Bernard B; Hofland LJ; Srinivasan A; van der Pluijm M; Bakker WH; Visser TJ; Krenning EP
    Anticancer Res; 1998; 18(1A):83-9. PubMed ID: 9568060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
    Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
    Melis M; Krenning EP; Bernard BF; Barone R; Visser TJ; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1136-43. PubMed ID: 15912401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
    Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.
    Melis M; Valkema R; Krenning EP; de Jong M
    J Nucl Med; 2012 May; 53(5):749-53. PubMed ID: 22496587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.
    Schottelius M; Wester HJ; Reubi JC; Senekowitsch-Schmidtke R; Schwaiger M
    Bioconjug Chem; 2002; 13(5):1021-30. PubMed ID: 12236784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
    Albert R; Smith-Jones P; Stolz B; Simeon C; Knecht H; Bruns C; Pless J
    Bioorg Med Chem Lett; 1998 May; 8(10):1207-10. PubMed ID: 9871736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of cleavable (Tyr3)-octreotate derivatives for longer intracellular probe residence.
    Whetstone PA; Akizawa H; Meares CF
    Bioconjug Chem; 2004; 15(3):647-57. PubMed ID: 15149193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide.
    Wester HJ; Brockmann J; Rösch F; Wutz W; Herzog H; Smith-Jones P; Stolz B; Bruns C; Stöcklin G
    Nucl Med Biol; 1997 May; 24(4):275-86. PubMed ID: 9257325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
    Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
    Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging Somatostatin Positive Tumors with Tyr
    Noor A; Van Zuylekom JK; Rudd SE; Roselt PD; Haskali MB; Yan E; Wheatcroft M; Hicks RJ; Cullinane C; Donnelly PS
    Bioconjug Chem; 2021 Jul; 32(7):1192-1203. PubMed ID: 33788556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
    Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
    Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.
    Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ
    Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulation and purification of therapeutic dose of
    Chakravarty R; Chakraborty S; Dash A
    Appl Radiat Isot; 2017 Mar; 121():1-5. PubMed ID: 28012419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs.
    Basu S; Abhyankar A; Kand P; Kumar R; Asopa R; Rajan MG; Nayak U; Shimpi H; Das T; Venkatesh M; Chakrabarty S; Banerjee S
    Nucl Med Commun; 2011 Jul; 32(7):654-8. PubMed ID: 21654355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.